Robust Sofinnova exit gives Ablynx chance of strategic independence
This article was originally published in Scrip
Executive Summary
The last major venture investor in Ablynx found institutional buyers on 18 November for the last of its shares in the company, and with that the Belgian mini-antibody developer completed a significant right of passage: it is now owned by accumulators rather than speculators. That, according to CEO Edwin Moses gives Ablynx' board the chance to make longer-term strategic plans for the business without the distraction of early investors' exit anxieties.